Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo debuts Rogaine Foam equivalent; Pfizer patent suit applies heat to J&J/McNeil; Merck KGaA consumer unit beats forecast; Abbott seeks expanded vitamin D3 use; Hi-Tech Pharmacal adds to homeopathics portfolio; more news In Brief.

You may also be interested in...



FDA Allows Adding Vitamin D To More Nutritional Products

The rule, for publication in the Aug. 12 Federal Register, allows vitamin D3 at 500 IU per 240 mL in meal replacement beverages not intended for special dietary use in reducing or maintaining body weight and at 1 IU per kilocalorie in foods used as a sole source of nutrition for enteral feeding.

FDA Allows Adding Vitamin D To More Nutritional Products

The rule, for publication in the Aug. 12 Federal Register, allows vitamin D3 at 500 IU per 240 mL in meal replacement beverages not intended for special dietary use in reducing or maintaining body weight and at 1 IU per kilocalorie in foods used as a sole source of nutrition for enteral feeding.

In Brief

Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel